Unit
- Discovery and target identification: Researchers identify a biological target involved in a disease and search for compounds that interact with it. This phase includes high-throughput screening and lead optimization, which can take three to five years and result in several candidate molecules for further testing.
- Preclinical research phase: Before human trials, candidate drugs undergo laboratory and animal studies to assess safety, toxicity, and pharmacokinetics. Data from this phase supports the Investigational New Drug (IND) application to regulators, typically lasting one to three years.
- Clinical trial phases: Phase I tests safety in a small group of healthy volunteers. Phase II evaluates efficacy and side effects in patients. Phase III confirms efficacy and monitors adverse reactions in large populations. Each phase has distinct endpoints and regulatory milestones.
- Regulatory review and approval: After successful Phase III trials, the sponsor submits a New Drug Application (NDA) or Biologics License Application (BLA) to regulatory agencies like the FDA or EMA. The review process evaluates safety, efficacy, and manufacturing quality, often requiring 10 to 12 months.
- Post-market surveillance: Once approved, the drug enters Phase IV, which includes ongoing safety monitoring, periodic reporting, and risk management. Regulators may require post-marketing studies to address specific safety questions or to evaluate long-term effects.
- Lifecycle management: Patent protection, generic competition, and new indications influence a drug's commercial strategy. Companies may develop new formulations, combination therapies, or extended-release versions to extend market exclusivity and patient access.
- Key stakeholders: Pharmaceutical companies, contract research organizations (CROs), regulatory authorities, ethics committees, investigators, and patients all contribute to the development process. Effective communication and coordination among these groups are essential for timely approvals.
- Regulatory frameworks: Different countries have unique requirements. The FDA in the United States, EMA in Europe, and PMDA in Japan each have guidelines that sponsors must follow. International harmonization efforts like ICH guidelines help standardize expectations across regions.
- Project management in drug development: Drug development managers apply specialized project management tools and techniques to track progress across multiple interdependent workstreams. They establish clear milestones, manage cross functional dependencies, and apply risk mitigation strategies to keep development programs on schedule and within budget constraints throughout the lifecycle.
- Risk management practices: Identifying, assessing, and mitigating risks is central to drug development management. Teams conduct regular risk assessments covering scientific, regulatory, operational, and financial domains. Proactive risk management reduces delays, prevents costly failures, and supports informed decision making across all phases of the product lifecycle.
- Quality assurance and compliance: Throughout all phases, quality assurance systems ensure that development activities adhere to Good Laboratory Practices, Good Clinical Practices, and Good Manufacturing Practices. Audits, standard operating procedures, and document control processes maintain data integrity and regulatory compliance across the entire development program.
Scope of Practice
Role: Drug Development Manager
Within scope:
- Overseeing the overall drug development plan and timeline across all phases
- Coordinating communication between research teams, clinical operations, and regulatory affairs
- Monitoring project budgets, milestones, and resource allocation
- Ensuring compliance with regulatory requirements and standard operating procedures
Outside scope:
- Conducting laboratory experiments or animal studies personally
- Interpreting clinical trial data for medical decisions
- Approving final regulatory submissions without expert review
- Deciding on drug pricing or market access strategies
Quick Revision
- The drug development lifecycle includes discovery, preclinical research, clinical trials, regulatory review, post-market surveillance, and lifecycle management.
- Each phase has specific goals, timelines, and regulatory requirements that shape project management.
- Key stakeholders include sponsors, CROs, regulators, ethics committees, investigators, and patients.
- A drug development manager coordinates activities, monitors compliance, and ensures efficient resource use across phases.